Latus Bio announces IND clearance of LTS-101 for CLN2 Disease and receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Latus Bio launches AI/ML strategy to transform AAV gene therapy, adds two leading experts in peptide and protein modeling to Scientific Advisory Board
Latus Bio strengthens executive team with appointments of Ainslie Little as COO and Katie Hewitt as interim CBO
Latus Bio announces publication of breakthrough research on novel AAV capsid variant for Huntington’s and Parkinson’s disease gene therapy
Latus Bio unveils AAV-Ep+ capsid variant capable of unprecedented protein production in the brain
Latus Bio announces data presentations in support of its preclinical Huntington’s disease gene therapy program
Latus Bio launches with state-of-the-art gene therapy development technologies, two lead product candidates, and an initial $54 Million in Series A financing
Optimized AAV capsids for basal ganglia diseases show robust potency and distribution
An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice
Current trends in gene therapy to treat inherited disorders of the brain
How capsid screening could unleash CNS genetic therapies at scale
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer's disease
Cochlear transduction via cerebrospinal fluid delivery of AAV in non-human primates
AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease
In Conversation with Jang-Ho Cha, Chief Scientific & Medical Officer, Latus Therapeutics
Spark co-founder launches new CNS gene therapy biotech with $54M
.png)
.png)
.png)
.png)
.png)
.png)
.png)